Biogen Executive and Leadership Team

Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the company's overarching strategy and operational execution. Viehbacher guides Biogen's mission to discover, develop, and commercialize therapies for serious neurological and neurodegenerative diseases. This leadership involves steering the company's portfolio, which includes treatments for multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders. Overseeing global operations, the President & Chief Executive Officer ensures alignment with advanced research in neuroscience, biologics, and gene-based therapies. By driving innovation and strategic partnerships, Christopher Viehbacher directly impacts the company's ability to address unmet medical needs and enhance patient outcomes worldwide. The executive's focus remains on advancing Biogen's scientific endeavors and solidifying its market position in the biotechnology sector.

Berta Benevento, the Deputy Chief Financial Officer at Biogen, supports the financial strategy and fiscal management of the organization. Benevento plays a crucial role in financial planning, budgeting, and reporting, ensuring the company's financial health and compliance with regulatory standards. This leadership position involves collaborating with the Chief Financial Officer to optimize resource allocation and drive financial performance across Biogen's global operations. Overseeing key financial operations, the Deputy Chief Financial Officer contributes to the strategic decision-making process, supporting the development and commercialization of therapies for serious neurological conditions. By ensuring robust financial oversight, Berta Benevento directly supports Biogen's commitment to scientific advancement and patient care.

Robert Kramer, the Executive Vice President & Chief Financial Officer at Biogen, directs the company's global financial strategy, planning, and management. Kramer oversees all aspects of financial operations, ensuring fiscal responsibility and driving sustainable growth for Biogen's innovative therapies in neurological and neurodegenerative diseases. This executive role involves managing capital allocation, investor relations, and financial risk, supporting the company's long-term objectives. Overseeing the finance division, the Executive Vice President & Chief Financial Officer ensures robust financial controls and strategic investment in research and development. By guiding Biogen's financial trajectory, Robert Kramer directly supports the company's commitment to scientific advancement and delivering life-changing treatments to patients worldwide.

Stephen Thompson, the Chief of Staff To The Head of Development at Biogen, supports the strategic direction and operational efficiency of the development division. Thompson facilitates communication and project management across various development teams, ensuring seamless progress in the discovery and advancement of novel therapies. This role involves coordinating key initiatives and providing critical support to the Head of Development, thereby accelerating the pipeline for neurological and neurodegenerative disease treatments. Overseeing critical administrative functions, the Chief of Staff To The Head of Development ensures that development milestones are met and that resources are optimally allocated. By driving cross-functional collaboration, Stephen Thompson contributes directly to Biogen's commitment to bringing life-changing medicines to patients.

James Rouse, the Vice President, Chief Information Officer at Biogen, architects and oversees the company's global information technology infrastructure and strategy. Rouse drives the digital transformation initiatives that support Biogen's core business functions, including research, development, and commercialization of therapies for neurological diseases. This leadership role involves ensuring the security, scalability, and reliability of all IT systems, enabling seamless operations across the organization. Overseeing the IT department, the Vice President, Chief Information Officer implements cutting-edge technologies to enhance data analytics, streamline workflows, and foster innovation in neuroscience and biologics research. By optimizing technological resources, James Rouse directly supports Biogen's mission to deliver groundbreaking treatments to patients worldwide.

Cynthia Jones, the Chief of Staff, HI-Bio at Biogen, provides strategic support and operational leadership within the HI-Bio division. Jones facilitates the execution of key initiatives and ensures alignment across various functional areas, driving progress in the development of innovative therapies. This role involves coordinating critical projects and enhancing communication channels to support the division's objectives in addressing neurological and neurodegenerative diseases. Overseeing strategic operations, the Chief of Staff, HI-Bio ensures efficient resource deployment and effective project management. By fostering collaboration and driving operational excellence, Cynthia Jones directly contributes to Biogen's mission of advancing scientific discovery and delivering impactful treatments to patients.

Guy Hadari, the Senior Vice President, Global Chief Information Officer at Biogen, leads the global information technology strategy and execution, ensuring robust digital infrastructure to support Biogen's mission. Hadari drives the implementation of advanced technological solutions that enhance research, development, and commercial operations for neurological and neurodegenerative disease therapies. This critical role involves overseeing the global IT landscape, ensuring data integrity, cybersecurity, and system scalability across all Biogen's international operations. Overseeing the global IT function, the Senior Vice President, Global Chief Information Officer champions digital innovation and operational efficiency. By leveraging technology, Guy Hadari directly supports Biogen's commitment to scientific breakthroughs and improving patient lives through innovative treatments.

Amy Wilson, the Head of Strategic Operations, Pharmaceutical Operations & Technology Chief of Staff at Biogen, directs strategic initiatives and operational enhancements within the Pharmaceutical Operations & Technology division. Wilson ensures the efficient and effective execution of manufacturing and technology processes critical to Biogen's therapeutic development. This leadership role involves optimizing supply chain logistics, enhancing operational workflows, and driving continuous improvement across global production facilities. Overseeing strategic operations, the Head of Strategic Operations, Pharmaceutical Operations & Technology Chief of Staff ensures alignment with Biogen's commitment to delivering high-quality treatments for neurological diseases. By driving operational excellence, Amy Wilson directly supports the company's ability to meet patient needs worldwide.

Monirath Pao, the Chief Marketing Officer & Quality Engineer at Biogen, leads the strategic marketing efforts and ensures quality standards across relevant operations. Pao drives the market positioning and commercialization strategies for Biogen's portfolio of therapies targeting serious neurological and neurodegenerative diseases. This dual role involves integrating quality engineering principles into marketing initiatives to ensure product integrity and patient safety. Overseeing marketing functions and quality assurance, the Chief Marketing Officer & Quality Engineer ensures that Biogen's treatments reach patients effectively and meet the highest standards. By championing both market reach and product excellence, Monirath Pao directly contributes to Biogen's mission of improving patient outcomes globally.

Krystin Hein, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) at Biogen, spearheads strategic planning and operational execution within the US Medical Affairs division, focusing on rare diseases and neuropsychiatry. Hein ensures the effective deployment of medical strategies and operational initiatives to support patient access and engagement with Biogen's therapies. This leadership role involves coordinating cross-functional teams to advance the company's mission in addressing complex neurological conditions. Overseeing US operations for rare disease and neuropsychiatry medical affairs, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) drives strategic alignment and operational efficiency. By leading these critical US-based initiatives, Krystin Hein directly contributes to Biogen's global efforts to improve the lives of patients with challenging neurological disorders.